Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 61 to 70 of 330

TitleReference numberPublishedLast updated
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Skin cancerQS130
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Ovarian cancer: recognition and initial managementCG122
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914

Results per page

  1. 10
  2. 25
  3. 50
  4. All